Pact Pharma Stock

pactpharma.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $354.6MM

PACT Pharma clinical stage biotechnology company developing personalized adoptive T cell therapies for the eradication of solid tumors.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value

Powered by Forge Data

Access valuation and stock price for companies like Pact Pharma.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Pact Pharma stock FAQs

plusminus

Can you buy Pact Pharma stock?

You can no longer buy Pact Pharma stock on a secondary marketplace as this company ceased its operations. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Pact Pharma stock?

You can no longer sell stock of Pact Pharma on Forge as this company ceased its operations. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

What is Pact Pharma’s stock price?

Pact Pharma ceased its operations so there is no stock price available.
plusminus

What is Pact Pharma’s stock ticker symbol?

Pact Pharma ceased its operations so there is no stock ticker symbol.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Team

Management Team

Alex Franzusoff Ph.D
Chief Scientific Officer
Antoni Ribas Ph.D
Scientific Co-Founder & Board Member
Timothy Moore
Chief Technical Officer & President
Juan Jaen Ph.D
Co-Founder & Board Member
James Heath Ph.D
Scientific Co-Founder & Board Member
David Baltimore Ph.D
Scientific Co-Founder & Chairman of Scientific Advisory Board
Terry Rosen Ph.D
Co-Founder & Board Member
Blake Byers Ph.D
Interim President & Board Member

Board Members

Antoni Ribas Ph.D
Juan Jaen Ph.D
Terry Rosen Ph.D
David Baltimore Ph.D
James Heath Ph.D
Blake Byers Ph.D
KT Moortgat Ph.D
AbbVie Ventures
PACT Pharma, a SouthSan Francisco, Calif.-based advancing personalized NeoTCR-T cell therapies to eradicate solid tumors, closed a $75m Series C financing
South San Francisco-based PACT Pharma, a provider of personalized cell therapy for solid tumors, has appointed Tim Moore as president and chief technical officer. Previously, Moore worked at Kite where he was executive vice president of technical operations. PACT Pharma's backers included GV, Canaan, Casdin Capital, Droia, Foresite Capital, Invus, Pontifax, Wu Capital, AbbVie Ventures and Taiho Ventures.
Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.